EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised

Sarah Acaster, Clara Mukuria, Donna Rowen, John E Brazier, Claire E Wainwright, Bradley S Quon, Jamie Duckers, Alexandra L Quittner, Yiyue Lou, Patrick R Sosnay, Lisa J McGarry

Value in Health · 2023-04 · 26 (4) · 567-578

DOI: 10.1016/j.jval.2022.12.002 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Value in Health, 2023-04. Verfasst von Sarah Acaster und 10 weiteren Autor:innen. Beteiligte Einrichtung: Acaster Lloyd Consulting Ltd, London, England, UK. Electronic address: sarah.acaster@acasterlloyd.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quality of Life. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Cystic fibrosis (CF) limits survival and negatively affects health-related quality of life (HRQOL). Cost-effectiveness analysis (CEA) may be used to make reimbursement decisions for new CF treatments; nevertheless, generic utility measures used in CEA, such as EQ-5D, are insensitive to meaningful changes in lung function and HRQOL in CF. Here we develop a new, CF disease-specific, preference-based utility measure based on the adolescent/adult version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a widely used, CF-specific, patient-reported measure of HRQOL. METHODS: Blinded CFQ-R data from 4 clinical trials (NCT02347657, NCT02392234, NCT01807923, and NCT01807949) were used to identify discriminating items for a classification system using psychometric (eg, factor and Rasch) analyses. Thirty-two health states were selected for a time trade-off (TTO) exercise with a representative sample of the UK general population. TTO utilities were used to estimate a preference-based scoring algorithm by regression analysis (tobit models with robust standard errors clustered on participants with censoring at -1). RESULTS: A classification system with 8 dimensions (CFQ-R-8 dimensions; physical functioning, vitality, emotion, role functioning, breathing difficulty, cough, abdominal pain, and body image) was generated. TTO was completed by 400 participants (mean age, 47.3 years; 49.8% female). Among the regression models evaluated, the tobit heteroscedastic-ordered model was preferred, with a predicted utility range from 0.236 to 1, no logical inconsistencies, and a mean absolute error of 0.032. CONCLUSION: The CFQ-R-8 dimensions is the first disease-specific, preference-based scoring algorithm for CF, enabling estimation of disease-specific utilities for CEA based on the well-validated and widely used CFQ-R.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuality of LifeAdolescentAdultFemaleHumansMaleMiddle AgedAlgorithmsPsychometricsSurveys and Questionnaires

Stichwörter der Autor:innen

Cystic Fibrosis Questionnaire-Revisedcost utilitycystic fibrosispatient-reported outcomesquality of life

Autor:innen und Institutionen

  • Acaster Lloyd Consulting Ltd, London, England, UK. Electronic address: sarah.acaster@acasterlloyd.com.
  • School of Health and Related Research, The University of Sheffield, Regent Court, Sheffield, England, UK.
  • Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia.
  • Centre for Heart Lung Innovation, St. Paul's Hospital, and Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Department of Respiratory Medicine, Cardiff and Vale University Health Board, NHS Wales, Cardiff, Wales, UK.
  • Research, Behavioral Health Systems Research, Miami, FL, USA.

Zitieren

APA

Acaster, S., Mukuria, C., Rowen, D., Brazier, J. E., Wainwright, C. E., Quon, B. S., Duckers, J., Quittner, A. L., Lou, Y., Sosnay, P. R., & McGarry, L. J. (2023). Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised. Value in Health, 26(4), 567-578. https://doi.org/10.1016/j.jval.2022.12.002

Vancouver

Acaster S, Mukuria C, Rowen D, Brazier JE, Wainwright CE, Quon BS, et al. Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised. Value in Health. 2023;26(4):567-578. doi:10.1016/j.jval.2022.12.002

BibTeX
@article{Acaster2023,
  author = {Acaster, Sarah and Mukuria, Clara and Rowen, Donna and Brazier, John E and Wainwright, Claire E and Quon, Bradley S and Duckers, Jamie and Quittner, Alexandra L and Lou, Yiyue and Sosnay, Patrick R and McGarry, Lisa J},
  title = {Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised},
  journal = {Value in Health},
  year = {2023},
  volume = {26},
  number = {4},
  pages = {567--578},
  doi = {10.1016/j.jval.2022.12.002}
}
Kostenlos starten →